

FOR HEALTHCARE PROFESSIONALS ONLY - NOT FOR DISTRIBUTION TO GENERAL PUBLIC.

A COMBINATION OF OLIGOSACCHARIDES DESIGNED TO CLOSELY MIMIC HUMAN MILK **OLIGOSACCHARIDES (HMOS) IN BREAST MILK**

HMOS ARE A DIVERSE POOL OF PREBIOTIC OLIGOSACCHARIDES¹

Prebiotics are non-digestible carbohydrate structures selectively utilized by host microorganisms conferring a health benefit to the host (ISAPP¹); also known as food for 'good bacteria'.





DIVERSITY

More than 1000 different HMOS

in breast milk, of which >200 have


been structurally identified⁴⁻⁶

HMOS are present in short chain (sc) and long chain (lc) oligosaccharides in a 9:1 ratio^{7,8}

For illustrative purposes only. Schematic representation of HMOS in breast milk.

FUNCTIONALITY

Functional benefits have been demonstrated for the diverse pool HMOS:







Healthy stool characteristics¹²



benefits^{10,13,14}




Brain building blocks^{10,15}


DANONE RESEARCH AND INNOVATION WAS THE FIRST TO INTRODUCE A PREBIOTIC MIXTURE scGOS/lcFOS (9:1)* IN 2000



FUNCTIONALITY OF THE DIVERSE POOL OF HMOS IN BREAST MILK^{7,8,16}

SCGOS/LCFOS (9:1) WAS CREATED TO HELP TO MIMIC THE QUANTITY, DIVERSITY AND







to support a healthy gut and immune system development by: Stimulating









Suppressing growth of pathogens^{19,20}




For illustrative purposes only. Schematic representation of scGOS/lcFOS (9:1).

*short-chain galacto-oligosaccharides (scGOS)/long-chain fructo-oligosaccharides (lcFOS) (9:1).

SINCE 2014, IDENTICAL HMO STRUCTURES HAVE BECOME AVAILABLE TO BE SUPPLEMENTED TO INFANT FORMULA²⁵ The number of commercially available HMO structures is increasing.

However, it is not yet possible to mimic the diverse and complex pool of HMOS in breast milk²⁵.



to be safe²⁶, further research on their functionality is needed.





Although HMOs have been demonstrated

For illustrative purposes only. Schematic representation of commercially available HMOs.

Our prebiotic mixture scGOS/lcFOS (9:1) ADDED TO OUR FORMULAS SINCE 2000

RECOGNIZED BY EXPERTS^{2,25}

CLINICALLY PROVEN¹⁷

THE DIVERSITY OF THE TOTAL POOL

OF OLIGOSACCHARIDES EXTENDS **EVEN FURTHER BY COMBINING** HMOs & scGOS/lcFOS (9:1)

& commercially available HMO

Combination of scGOS/lcFOS (9:1)

For illustrative purposes only. Schematic representation of scGOS/lcFOS (9:1) and commercially available HMO (2'-FL).

- Thurl S et al. Nutr Rev. 2017;75(11):920-33.
- References: Gibson G et al. Nat Rev Gastroenterol Hepatol. 2017;14(8):491-502. Thurl S et al. Br J Nutr. 2010;104(9):1261-1271.
- Kunz C et al. Annu. Rev. Nutr. 2000;20:699-722 Urashima T et al. 2018;30(172):SE51-SE65.
- Orczyk-Pawiłowicz P et al. Nutrients. 2020;12(4):1105. Stahl B et al. Anal Biochem. 1994:223;218-26.
- Boehm G et al. Acta Paediatr Suppl. 2003;91(441):64-67. Wickramasinghe S et al. BMC Microbiol. 2015;15:172.
- Bode L. Glycobiology. 2012;22(9):1147-62. Walsh C et al. J Funct Foods. 2020;72:104074.
- Scholtens PA et al. World J Gastroenterol. 2014;20(37):13446-13452.

Siziba LP et al. Nutrients. 2021;13(6):1973.

Data on file, Danone Research & Innovation.

Bode L et al. Thromb Haemost. 2004;92(6):1402-10. Newburg DS et al. Glycobiology. 2004;14 (3) 253-63. Wang S et al. Neurosci Biobehav Rev. 2018;95:191-201.

Moro G et al. J Pediatr Gastroenterol Nutr. 2002;34(3):291-295.

- Knol J et al. J Pediatr Gastroenterol Nutr. 2005;40(1):36-42. Scholtens PA et al. J Nutr. 2008;138(6):1141-1147.
 - Arslanoglu S et al. J Nutr. 2007;137(11):2420-2424. Arslanoglu S et al. J Nutr. 2008;138(6):1091-1095.
 - Chatchatee P et al. J Pediatr Gastroenterol Nutr. 2014;58(4):428-437. Cool R & Vandenplas Y. Nutrients. 2023;15(8):1942. Parschat K et al. Nutrients. 2021;13(8):2871.

Bruzzese E et al. Clin Nutr. 2009;28(2):156-61.